NDC product
OPDUALAG
NDC 0003-7125 · E.R. Squibb & Sons, L.L.C.
Key facts
| Product NDC | 0003-7125 |
|---|---|
| Proprietary name | OPDUALAG |
| Nonproprietary name | nivolumab and relatlimab-rmbw |
| Substances | NIVOLUMAB, RELATLIMAB |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | E.R. Squibb & Sons, L.L.C. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761234 |
| Pharmacologic classes | Lymphocyte Activation Gene-3 Antagonists [MoA], Lymphocyte Activation Gene-3 Blocker [EPC], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
| Marketing start | Mar 18, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: